TBC1D2B Inhibitors
TBC1D2B inhibitors chiefly act upon pathways associated with GTPase functions. Zoledronic acid and GGTI-298, for instance, target the modification process of Rab GTPases, specifically their prenylation. When these GTPases are not properly modified, their cellular localization and function can be impaired, which in turn affects proteins like TBC1D2B that regulate them.
SecinH3, Brefeldin A, and Clostridium difficile toxin B are other noteworthy compounds. While SecinH3 impedes the activation of Arf GTPases, potentially influencing TBC1D2B indirectly through altered vesicle transport, Brefeldin A suppresses ARF-GEFs directly, leading to broad disruptions in vesicular trafficking. Clostridium difficile toxin B targets Rho GTPases, with cascading effects that can reach TBC1D2B. Similarly, by inhibiting other GTPases, such as Rac1 and Cdc42, NSC23766 and ML141 can indirectly affect the role of TBC1D2B in cellular processes. The class also includes broader spectrum agents like LY294002 and Wortmannin that impact PI3K signaling, and Neomycin targeting phospholipase C. The influence of these inhibitors on vesicle transport and associated pathways can indirectly modulate TBC1D2B activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Zoledronic acid, anhydrous | 118072-93-8 | sc-364663 sc-364663A | 25 mg 100 mg | $90.00 $251.00 | 5 | |
Inhibits the prenylation of Rab proteins, hindering their function. This can indirectly suppress TBC1D2B's regulatory role. | ||||||
GGTI 298 | 1217457-86-7 | sc-361184 sc-361184A | 1 mg 5 mg | $189.00 $822.00 | 2 | |
By blocking geranylgeranyl transferase, it affects the post-translational modification of Rab GTPases, potentially impinging on TBC1D2B's role in their regulation. | ||||||
SecinH3 | 853625-60-2 | sc-203260 | 5 mg | $273.00 | 6 | |
Inhibits cytohesins, preventing the activation of Arf GTPases. This disruption in vesicle transport can affect TBC1D2B indirectly. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Suppresses ARF-GEFs, leading to vesicular trafficking disruption, which may in turn influence TBC1D2B's Rab GTPase modulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
By inhibiting PI3K signaling, vesicle transport regulation can be impacted, possibly affecting TBC1D2B's activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Similar to LY294002, its inhibition of PI3K can disrupt vesicle transport pathways, indirectly affecting TBC1D2B. | ||||||
Neomycin sulfate | 1405-10-3 | sc-3573 sc-3573A | 1 g 5 g | $26.00 $34.00 | 20 | |
By inhibiting phospholipase C, it modulates GTPase regulation, potentially affecting TBC1D2B's Rab GTPase regulatory function. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $134.00 $502.00 | 7 | |
By inhibiting Cdc42 GTPase, it alters cytoskeleton dynamics and vesicle movement, possibly influencing TBC1D2B indirectly. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $28.00 $88.00 $332.00 | 12 | |
Suppressing HMG-CoA reductase leads to reduced prenylation and function of Rab GTPases, potentially affecting TBC1D2B's regulatory role. | ||||||